Indian films

Cedar Announces Krishna Rao as Chief Financial Officer

Retrieved on: 
Tuesday, August 3, 2021

NEW YORK, Aug. 3, 2021 /PRNewswire/ -- Cedar , an innovative healthcare financial technology platform, today announced it has named Krishna Rao as Cedar's first Chief Financial Officer (CFO).

Key Points: 
  • NEW YORK, Aug. 3, 2021 /PRNewswire/ -- Cedar , an innovative healthcare financial technology platform, today announced it has named Krishna Rao as Cedar's first Chief Financial Officer (CFO).
  • In this role, Rao will oversee Cedar's comprehensive finance and legal function, helping to drive strategic growth and decision-making for the company.
  • "Krishna has a proven track record of guiding companies through the next level of performance and growth," said Florian Otto, CEO and co-founder of Cedar.
  • "The problem Cedar is solving is so tangible almost everyone has experienced a frustrating or confusing medical bill," said Rao.

Lunchbox Acquires Spread to Create an Industry-first No-commission Delivery Platform

Retrieved on: 
Tuesday, August 3, 2021

This platform also has multiple applications and can be focused on target neighborhoods or even be used as a city-run marketplace.

Key Points: 
  • This platform also has multiple applications and can be focused on target neighborhoods or even be used as a city-run marketplace.
  • The Spread marketplace launched in late 2020 in New York City with 1,500+ restaurants on the platform and $3M+ orders.
  • I'm thrilled to be joining the Lunchbox team to spearhead this new platform and help restaurants see greater returns."
  • This acquisition will push Lunchbox beyond a white-labeled ordering platform to create one of the most unique platforms available in the restaurant industry.

Athira Pharma to Present ATH-1017 Phase 1 Translational Data at the Alzheimer’s Association International Conference 2021 (AAIC)

Retrieved on: 
Monday, July 19, 2021

The poster will also be available on the Events & Presentations page of the Athira website https://investors.athira.com/news-and-events/events-and-presentations .

Key Points: 
  • The poster will also be available on the Events & Presentations page of the Athira website https://investors.athira.com/news-and-events/events-and-presentations .
  • Athira is currently advancing its lead therapeutic candidate, ATH-1017, a novel small molecule for Alzheimers and Parkinsons dementia.
  • These forward-looking statements speak only as of the date hereof and Athira undertakes no obligation to update forward-looking statements.
  • Athira may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the forward-looking statements.

J.Jill, Inc. Appoints Jyothi Rao to Board of Directors

Retrieved on: 
Monday, July 12, 2021

J.Jill, Inc. (NYSE:JILL) has announced the appointment of Jyothi Rao to its Board of Directors, effective July 12, 2021.

Key Points: 
  • J.Jill, Inc. (NYSE:JILL) has announced the appointment of Jyothi Rao to its Board of Directors, effective July 12, 2021.
  • We are delighted that Jyothi will be joining the J.Jill Board, said Michael Rahamim, J.Jills Chairman.
  • Claire Spofford, J.Jills CEO and President, also welcomed Ms. Rao: Jyothi brings extensive knowledge of the retail landscape, and I look forward to adding such a talented female leader to our board.
  • I am thrilled to be joining J. Jill's Board of Directors, said Ms. Rao.

SHAREHOLDER ALERT: Robbins LLP Announces that Athira Pharma, Inc. (ATHA) is Being Sued for Misleading Shareholders

Retrieved on: 
Friday, July 9, 2021

Shareholder rights law firm Robbins LLP announces that several class actions have been filed on behalf of all purchasers of Athira Pharma, Inc. (NASDAQ: ATHA) who acquired Athira securities between September 18, 2020 and June 17, 2021.

Key Points: 
  • Shareholder rights law firm Robbins LLP announces that several class actions have been filed on behalf of all purchasers of Athira Pharma, Inc. (NASDAQ: ATHA) who acquired Athira securities between September 18, 2020 and June 17, 2021.
  • Athira is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration for those suffering from devastating neurological diseases, including Alzheimer's diseases.
  • If you suffered a loss due to Athira Pharma, Inc.'s misconduct, click here .
  • And so Kawas' doctoral work laid the biological groundwork that Athira continues to use in their approach to treating Alzheimer's."

SHAREHOLDER ALERT: Robbins LLP Announces that Athira Pharam, Inc. (ATHA) is Being Sued for Misleading Shareholders

Retrieved on: 
Thursday, July 1, 2021

Shareholder rights law firm Robbins LLP announces that several class actions have been filed on behalf of all purchasers of Athira Pharma, Inc. (NASDAQ: ATHA) who acquired Athira securities between September 18, 2020 and June 17, 2021.

Key Points: 
  • Shareholder rights law firm Robbins LLP announces that several class actions have been filed on behalf of all purchasers of Athira Pharma, Inc. (NASDAQ: ATHA) who acquired Athira securities between September 18, 2020 and June 17, 2021.
  • Athira is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration for those suffering from devastating neurological diseases, including Alzheimer's diseases.
  • If you suffered a loss due to Athira Pharma, Inc.'s misconduct, click here .
  • And so Kawas' doctoral work laid the biological groundwork that Athira continues to use in their approach to treating Alzheimer's."

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Athira Pharma, Inc. (ATHA) Investors

Retrieved on: 
Wednesday, June 30, 2021

Athira investors have until August 24, 2021 to file a lead plaintiff motion.

Key Points: 
  • Athira investors have until August 24, 2021 to file a lead plaintiff motion.
  • If you are a shareholder who suffered a loss, click here to participate.
  • Athira is a late-stage clinical biopharmaceutical company that is focused on developing small molecules to restore neuronal health and stop neurodegeneration.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Q India Announces Five Exclusive Comedy Series

Retrieved on: 
Wednesday, June 30, 2021

In addition, The Q also secured exclusive rights to hit social comedy series Chu Chu Ke Funs, Yogesh Kathuria and Dum Laga ke Hasna.

Key Points: 
  • In addition, The Q also secured exclusive rights to hit social comedy series Chu Chu Ke Funs, Yogesh Kathuria and Dum Laga ke Hasna.
  • Comedy has proven to be a big winner for Q India which has now averaged over 45 GRP (Gross Rating Points as measured by BARC...the "Nielsen of India") for 11 consecutive weeks.
  • Number one rated comedy series Baklol, has accelerated a push to offer The Q fan base more comedy programming throughout the summer season.
  • Upcoming exclusive comedy series launching in July and August include:
    Yogesh Kathuria: Ever wondered what Indian fathers are like?

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Athira Pharma, Inc. (ATHA) Investors

Retrieved on: 
Monday, June 28, 2021

Athira investors have until August 24, 2021 to file a lead plaintiff motion.

Key Points: 
  • Athira investors have until August 24, 2021 to file a lead plaintiff motion.
  • Investors suffering losses on their Athira investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected] .
  • Athira is a late-stage clinical biopharmaceutical company that is focused on developing small molecules to restore neuronal health and stop neurodegeneration.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Dr. Surajit Khanna's Returning Youth Initiative Selects Indigo Station LLC as its PR Agency

Retrieved on: 
Friday, June 25, 2021

Dr. Khanna's Returning Youth Initiative works nationally to positively impact young adults released from any type of government confinement.

Key Points: 
  • Dr. Khanna's Returning Youth Initiative works nationally to positively impact young adults released from any type of government confinement.
  • Speaking for Indigo Station, Heather Malloy Davis says, "We are excited to work with Dr. Khanna and the Returning Youth Initiative team.
  • Indigo Station, working with Dr. Khanna and the Returning Youth Initiative, expects to deliver on this promise as it expands to all 50 states and 3,142 counties in the USA."
  • About Dr. Khanna's Returning Youth Initiative: Dr. Surajit Khanna, a youth advocate, launched "Returning Youth" to provide post-incarceration young adults a pathway to reintegrate into the society when they are released from prison so that they can create a self-sustaining productive life for themselves and their families.